Low-dose methotrexate, the kind prescribed for rheumatoid arthritis and other autoimmune conditions, does not shorten life expectancy. The evidence actually points in the opposite direction: people with rheumatoid arthritis who take methotrexate tend to live longer than those who don’t. One study found methotrexate use was associated with a 70% reduction in mortality risk among RA patients after adjusting for other factors. The concern is understandable, since methotrexate is also a chemotherapy drug, but the doses used for autoimmune diseases are fundamentally different from those used in cancer treatment.
Two Very Different Doses, Two Very Different Drugs
Much of the fear around methotrexate comes from its reputation as a cancer drug. In oncology, methotrexate is given at doses many times higher than the amount prescribed for conditions like rheumatoid arthritis, psoriasis, or inflammatory bowel disease. Researchers have pointed out that low-dose and high-dose methotrexate are essentially two different drugs in practical terms, with different mechanisms of action, different side effect profiles, and different clinical purposes.
For autoimmune conditions, a typical dose ranges from about 7.5 to 25 milligrams per week. In cancer treatment, doses can reach several grams per square meter of body surface area, delivered intravenously. The toxicity risks that come with chemotherapy-level dosing simply don’t apply at the low doses used for inflammation. Understanding this distinction is the single most important thing for calming concerns about the drug’s effect on lifespan.
Why It May Actually Help You Live Longer
Rheumatoid arthritis itself shortens life expectancy. Chronic, uncontrolled inflammation damages blood vessels, increases the risk of heart attack and stroke, and accelerates processes throughout the body that lead to early death. By suppressing that inflammation, methotrexate addresses one of the main reasons RA patients die younger than the general population.
The cardiovascular benefits are particularly striking. In a large multicenter RA cohort, methotrexate use was linked to a 30% reduced risk of major cardiovascular events, including heart attack, stroke, and the need for coronary procedures. The risk of hospitalization for heart failure dropped by 60%. Importantly, this protective effect was independent of how well methotrexate controlled the arthritis itself, suggesting the drug reduces cardiovascular risk through additional mechanisms beyond just quieting joint inflammation.
This is a big deal because heart disease is the leading killer of people with RA. A drug that both controls the disease and independently protects the heart has a meaningful impact on how long someone lives.
Liver Risks Over the Long Term
Liver damage is the side effect people worry about most, and it’s a legitimate concern that requires monitoring. A meta-analysis of patients on long-term methotrexate found that about 27% showed some degree of liver changes on biopsy, but only 5% developed advanced fibrosis or cirrhosis. Those numbers deserve context: most of the progression was mild, and regular blood tests catch problems early enough to adjust or stop the medication before serious damage occurs.
Your baseline liver health matters. In a large retrospective study, patients who had metabolic syndrome (a cluster of conditions including obesity, high blood sugar, and abnormal cholesterol) alongside methotrexate use had higher rates of cirrhosis at 10 years: about 2% compared to 1% in controls. For patients who also had fatty liver disease, that gap widened to 4% versus 2%. For people without these metabolic risk factors, the additional liver risk from methotrexate was quite small.
Current guidelines recommend blood tests every three months for established patients to monitor liver enzymes and blood counts. This routine screening is the main reason serious liver complications remain uncommon. If your numbers start trending in the wrong direction, your doctor can intervene well before any lasting damage occurs.
Infection Risk Is Lower Than You’d Expect
Because methotrexate suppresses part of the immune system, there’s a reasonable assumption that it would make infections more dangerous. A systematic review and meta-analysis found a more nuanced picture. In RA patients specifically, methotrexate was associated with roughly 88 additional infections per 1,000 patients compared to placebo, most of them mild. In people taking methotrexate for other inflammatory conditions, the additional infection risk was negligible: about 7 extra infections per 1,000 patients.
Crucially, there was no increased risk of serious infections (those requiring hospitalization or intravenous antibiotics) across any of the inflammatory disease populations studied. The infections that do occur tend to be routine ones like colds and upper respiratory infections, not life-threatening opportunistic infections.
Lung Complications Are Rare but Real
Methotrexate can cause a type of lung inflammation called pneumonitis. In populations with rheumatoid arthritis, estimates range from 0.3% to 11.6%, a wide range that reflects differences in how the condition is defined and detected across studies. Pneumonitis typically develops within the first year of treatment and presents with a dry cough, shortness of breath, and fever. It’s a serious side effect, but it’s also reversible when caught early and the drug is stopped.
For people who already have lung disease related to their autoimmune condition, the picture is more complicated. A study of patients with dermatomyositis found no significant difference in interstitial lung disease rates between those who received methotrexate and those who didn’t. But researchers have cautioned against interpreting this as proof of safety, since the studies were too small to rule out a meaningful increase in risk. If you have pre-existing lung problems, your doctor will weigh this more carefully.
What Actually Determines Your Outcome
The biggest threat to life expectancy for someone with rheumatoid arthritis or a similar inflammatory condition isn’t methotrexate. It’s undertreated disease. Uncontrolled inflammation drives atherosclerosis, increases cancer risk, and damages organs over decades. People who stop or avoid effective treatment out of fear of side effects often face worse long-term outcomes than those who take the medication with proper monitoring.
The factors that most influence whether methotrexate stays safe over the long term are things you can track and manage: keeping up with regular blood work, maintaining a healthy weight, limiting alcohol (which compounds liver stress), and staying aware of new symptoms like persistent cough or unusual fatigue. Folic acid supplementation, which most doctors prescribe alongside methotrexate, significantly reduces side effects like nausea, mouth sores, and abnormal liver tests.
For the vast majority of people on low-dose methotrexate, the drug doesn’t shorten life. It extends it, by controlling a disease that would otherwise quietly take years off.